First test of HB2198 in healthy adults
This study tests a single dose of an experimental therapy (HB2198) in healthy volunteers to see how the body handles it. It is a first-in-human trial designed to check safety and how the drug affects your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old and in good general health.
- Your baseline blood test shows normal levels of antibodies (IgG) and B cells.
- You are not pregnant, breastfeeding, or planning to have a child in the next 6 months.
- You have no active or recent serious infections, and no chronic use of antivirals or antibiotics.
- You have not had a live vaccine in the last 30 days (or a non-live vaccine within the last 14 days).
- You agree to stay at the study clinic from the day before your dose until at least 24 hours after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody-based drug in healthy volunteers to see how safe it is and how the body handles it. Participants will receive a single injection and be monitored closely for a few months.
This trial tests a single dose of a new medicine called HB0056 in healthy volunteers to evaluate its safety and how the body processes it. If you are a healthy adult, you may help doctors understand if this drug is safe for future studies.
This early-phase trial tests a new antibody-based therapy called SCTB10 in healthy volunteers to see if it's safe and how the body processes it. Participation can help determine the right dose for future patients.
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
This trial tests a single dose of an investigational drug called HC022 in healthy volunteers to see how safe it is and how the body handles it. If you are a healthy adult, you may be able to join and help researchers learn the first steps about this new medicine.
This Phase 1 study tests an investigational treatment for adults with lymphoma that has come back or did not respond to prior treatments. It targets lymphoma cells that have CD19 and CD20 markers, aiming to reduce or control the disease in people with limited options.
Hear when a new Healthy Volunteer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.